Nurix Therapeutics, Inc.
NRIX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001549595
In the last 90 days, Nurix Therapeutics, Inc. insiders filed 0 open-market purchases and 10 sales; 211 institutions reported holding it in 13F filings for Q2 2026, worth $2.84B in total; ARK Invest is the only superinvestor holding it.
13F holders, Q3 2022
Institutional positions in Nurix Therapeutics, Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 118
- +12 vs. Q2 2022
- Shares held
- 43.1M
- −1.94M (−4.3%) vs. Q2 2022
- Total value
- $561.0M
- −$7.49M (−1.3%) vs. Q2 2022
- New holders
- 20
- 51 more added
- Sold out
- 8
- 23 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NRIX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 211 | $2.84B |
| Q1 2026 | 196 | $1.81B |
| Q4 2025 | 182 | $2.15B |
| Q3 2025 | 173 | $783.3M |
| Q2 2025 | 164 | $1.01B |
| Q1 2025 | 170 | $1.01B |
| Q4 2024 | 175 | $1.53B |
| Q3 2024 | 172 | $1.53B |
| Q2 2024 | 174 | $1.36B |
| Q1 2024 | 139 | $721.3M |
| Q4 2023 | 131 | $475.6M |
| Q3 2023 | 129 | $352.5M |
| Q2 2023 | 126 | $435.7M |
| Q1 2023 | 124 | $376.6M |
| Q4 2022 | 119 | $468.6M |
| Q3 2022 | 118 | $561.0M |
| Q2 2022 | 106 | $568.4M |
| Q1 2022 | 117 | $565.6M |
| Q4 2021 | 125 | $1.17B |
| Q3 2021 | 113 | $1.18B |
| Q2 2021 | 104 | $1.05B |
| Q1 2021 | 101 | $1.29B |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Nurix Therapeutics, Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Millennium Management LLC | 739,925 | $9.64M | 0.01% | −72,003−8.9% | Reduced |
| Geode Capital Management, LLC | 816,462 | $10.6M | 0.00% | +43,168+5.6% | Added |
| Goldman Sachs Group Inc | 825,079 | $10.8M | 0.00% | +493,236+148.6% | Added |
| Candriam Luxembourg S.C.A. | 825,575 | $10.8M | 0.08% | −13,800−1.6% | Reduced |
| T. Rowe Price Investment Management, Inc. | 992,428 | $12.9M | 0.01% | +992,428 | New |
| Pictet Asset Management SA | 1,076,349 | $14.0M | 0.02% | −354,016−24.8% | Reduced |
| Boxer Capital, LLC | 1,224,892 | $16.0M | 0.90% | 00.0% | Unchanged |
| ARK Investment Management LLCSuperinvestorARK Invest | 1,286,522 | $16.8M | 0.12% | +507,797+65.2% | Added |
| FMR LLC | 1,685,651 | $22.0M | 0.00% | −105,004−5.9% | Reduced |
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $23.8M | 2.84% | 00.0% | Unchanged |
| Deep Track Capital, LP | 2,053,621 | $26.8M | 1.32% | −382,543−15.7% | Reduced |
| Vanguard Group Inc | 2,160,866 | $28.2M | 0.00% | +49,370+2.3% | Added |
| State Street Corp | 2,312,224 | $30.1M | 0.00% | +195,453+9.2% | Added |
| Wasatch Advisors Inc | 2,657,437 | $34.6M | 0.24% | +394,374+17.4% | Added |
| Redmile Group, LLC | 3,006,684 | $39.2M | 1.52% | 00.0% | Unchanged |
| Price T Rowe Associates Inc | 3,606,352 | $47.0M | 0.01% | −1,014,471−22.0% | Reduced |
| BlackRock Inc. | 3,723,090 | $48.5M | 0.00% | +367,743+11.0% | Added |
| Baker Bros. Advisors LP | 3,882,125 | $50.6M | 0.33% | 00.0% | Unchanged |
| TRV GP III, LLC | 0 | $0 | 0.00% | −1,922,549−100.0% | Sold out |
| Eventide Asset Management, LLC | 0 | $0 | 0.00% | −1,154,000−100.0% | Sold out |
| Foresite Capital Management IV, LLC | 0 | $0 | 0.00% | −677,143−100.0% | Sold out |
| Bank of Montreal | 0 | $0 | 0.00% | −24,104−100.0% | Sold out |
| Fred Alger Management, LLC | 0 | $0 | 0.00% | −7,306−100.0% | Sold out |
| Prospera Financial Services Inc | 0 | $0 | 0.00% | −200−100.0% | Sold out |
| State of Wyoming | 0 | $0 | 0.00% | −209−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −100−100.0% | Sold out |